Table A1.
Distribution of Anthracycline Derivatives With Known Doses in Each Cohort
| Anthracycline or Anthraquinone | CCSS (n = 13,060) |
EKZ/AMC (n = 1,362) |
NWTS (n = 364) |
SJLIFE (n = 1,695) |
||||
|---|---|---|---|---|---|---|---|---|
| No. | %* | No. | %* | No. | %* | No. | %* | |
| None | 7,506 | 57.5 | 798 | 58.6 | 179 | 49.2 | 692 | 40.8 |
| Doxorubicin | 3,416 | 26.2 | 392 | 28.8 | 179 | 49.2 | 572 | 33.7 |
| Daunorubicin | 1,425 | 10.9 | 138 | 10.1 | 0 | 450 | 26.5 | |
| Idarubicin | 1 | 0.0 | 3 | 0.2 | 0 | 14 | 0.8 | |
| Epirubicin | 0† | 132 | 9.7 | 0 | 3 | 0.2 | ||
| Mitoxantrone | 0† | 25 | 1.8 | 0 | 18 | 1.1 | ||
| Unknown dose information | 1,194 | 9.1 | 9 | 0.7 | 6 | 1.6 | 5 | 0.3 |
Abbreviations: CCSS, Childhood Cancer Survivor Study; EKZ/AMC, Emma Children's Hospital and Academic Medical Center; NWTS, National Wilms Tumor Study; SJLIFE, St Jude Lifetime Cohort.
*
Total percentages may exceed 100% because some patients may have received > one type of anthracycline.
†
Epirubicin and mitoxantrone were administered to four and 11 individuals, respectively, but doses were unknown.